Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Salmeterol xinafoate |
Is a |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Product containing salmeterol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Salmeterol adverse reaction |
Causative agent (attribute) |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Allergy to salmeterol |
Causative agent (attribute) |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol 25mcg inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol 50micrograms/blister disks+disk inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol 50micrograms/blister disks refill |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol 50micrograms breath-actuated dry powder inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol+fluticasone propionate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol+fluticasone propionate 25micrograms/50micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol+fluticasone propionate 25micrograms/250micrograms CFC-free inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol+fluticasone propionate 50micrograms/100micrograms breath-actuated dry powder inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol+fluticasone propionate 50micrograms/250micrograms breath-actuated dry powder inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol+fluticasone propionate 50micrograms/500micrograms breath-actuated dry powder inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Product containing fluticasone and salmeterol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Fluticasone propionate + salmeterol xinafoate 250mcg/50mcg powder for oral inhalation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Fluticasone propionate + salmeterol xinafoate 500mcg/50mcg powder for oral inhalation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Fluticasone propionate + salmeterol xinafoate 100mcg/50mcg powder for oral inhalation (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Allergy to salmeterol |
Causative agent (attribute) |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Salmeterol xinafoate |
This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol+fluticasone propionate 25micrograms/250micrograms inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol+fluticasone propionate 25micrograms/125micrograms inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol+fluticasone propionate 25micrograms/50micrograms inhaler |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
|
Salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Fluticasone propionate 50 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
False |
Salmeterol (substance) |
Inferred relationship |
Some |
2 |
Fluticasone propionate 100 microgram and salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Fluticasone propionate 500 microgram and salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Fluticasone propionate 250 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Fluticasone propionate 125 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Fluticasone propionate 250 microgram and salmeterol (as salmeterol xinafoate) 50 microgram/actuation powder for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Product containing salmeterol in pulmonary dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Product containing fluticasone and salmeterol in pulmonary dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Product containing only fluticasone and salmeterol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Product containing only salmeterol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Fluticasone and salmeterol only product in pulmonary dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Salmeterol only product in pulmonary dose form |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Product containing precisely salmeterol (as salmeterol xinafoate) 21 microgram/1 actuation conventional release solution for inhalation (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |
Fluticasone propionate 50 microgram and salmeterol (as salmeterol xinafoate) 25 microgram/actuation pressurized suspension for inhalation |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Salmeterol (substance) |
Inferred relationship |
Some |
1 |